- $96.00m
- $244.00m
- $278.30m
- 42
- 61
- 17
- 33
Annual income statement for Cardlytics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 187 | 267 | 299 | 309 | 278 |
| Cost of Revenue | |||||
| Gross Profit | 81.5 | 130 | 143 | 159 | 151 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 241 | 390 | 756 | 445 | 461 |
| Operating Profit | -53.9 | -123 | -458 | -136 | -182 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -55.4 | -136 | -467 | -135 | -189 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -55.4 | -129 | -465 | -135 | -189 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -55.4 | -129 | -465 | -135 | -189 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -55.4 | -129 | -465 | -135 | -189 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.95 | -3.46 | -5.04 | -1.81 | -1.46 |